Logo image of BSLK

BOLT PROJECTS HOLDINGS INC (BSLK) Stock Fundamental Analysis

NASDAQ:BSLK - Nasdaq - US09769B1070 - Common Stock - Currency: USD

7.13  +1.82 (+34.27%)

After market: 6.81 -0.32 (-4.49%)

Fundamental Rating

0

Overall BSLK gets a fundamental rating of 0 out of 10. We evaluated BSLK against 85 industry peers in the Chemicals industry. Both the profitability and financial health of BSLK have multiple concerns. BSLK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BSLK has reported negative net income.
BSLK had a negative operating cash flow in the past year.
BSLK Yearly Net Income VS EBIT VS OCF VS FCFBSLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 2M -2M 4M 6M 8M

1.2 Ratios

The Return On Assets of BSLK (-53.55%) is worse than 94.12% of its industry peers.
Industry RankSector Rank
ROA -53.55%
ROE N/A
ROIC N/A
ROA(3y)-5.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSLK Yearly ROA, ROE, ROICBSLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BSLK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSLK Yearly Profit, Operating, Gross MarginsBSLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for BSLK has been reduced compared to 1 year ago.
The debt/assets ratio for BSLK is higher compared to a year ago.
BSLK Yearly Shares OutstandingBSLK Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
BSLK Yearly Total Debt VS Total AssetsBSLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.83, we must say that BSLK is in the distress zone and has some risk of bankruptcy.
BSLK has a worse Altman-Z score (-0.83) than 83.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.83
ROIC/WACCN/A
WACCN/A
BSLK Yearly LT Debt VS Equity VS FCFBSLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

BSLK has a Current Ratio of 0.02. This is a bad value and indicates that BSLK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.02, BSLK is not doing good in the industry: 96.47% of the companies in the same industry are doing better.
BSLK has a Quick Ratio of 0.02. This is a bad value and indicates that BSLK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.02, BSLK is not doing good in the industry: 96.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
BSLK Yearly Current Assets VS Current LiabilitesBSLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for BSLK have decreased strongly by -227.48% in the last year.
EPS 1Y (TTM)-227.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BSLK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BSLK Price Earnings VS Forward Price EarningsBSLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSLK Per share dataBSLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BSLK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOLT PROJECTS HOLDINGS INC

NASDAQ:BSLK (4/23/2025, 8:00:01 PM)

After market: 6.81 -0.32 (-4.49%)

7.13

+1.82 (+34.27%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners38.83%
Inst Owner Change0.58%
Ins Owners5.64%
Ins Owner Change-5.28%
Market Cap245.13M
AnalystsN/A
Price TargetN/A
Short Float %1.22%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.37
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -0.83
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-227.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.86%
OCF growth 3YN/A
OCF growth 5YN/A